Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Evotec SE ADR(EVO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EVO
11/06/2026: EVO (1-star) is currently NOT-A-BUY. Pass it for now.
Evotec SE is a life sciences services company that provides drug discovery and development platforms to the global pharmaceutical industry. The firm is recognized for its unique 'R&D powerhouse' model, which combines reliable service-based revenues with high-upside potential from milestone payments and royalty streams. While its AI-driven platforms and biologics manufacturing capabilities offer significant growth opportunities, the company faces risks related to pharmaceutical R&D spending volatility, execution challenges, and intense competition from larger CROs. Evotec may best suit growth-oriented investors who can tolerate biotechnology-sector volatility. Key developments to monitor include successful pipeline milestones, biologics manufacturing capacity expansion, and changes in global pharmaceutical R&D budget trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Evotec is built on a high-growth platform model focused on the innovation-heavy pharmaceutical R&D market. |
| Momentum investor | Mixed fit | This style is conditional on positive market sentiment regarding biotech R&D cycles and clinical success rates. |
| Value investor | Weak fit | The company's valuation is driven more by future technological potential and pipeline milestones than current cash yields. |
| Dividend investor | Weak fit | Evotec does not pay a dividend and prioritizes capital reinvestment into research and operations. |
| Low-risk investor | Weak fit | The stock is subject to inherent volatility common in the biotechnology and life sciences services sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is sensitive to sector-wide biotech news and R&D spending trends. |
| Valuation risk | Medium / high | As a growth-oriented firm, valuation is susceptible to changes in discount rates and future earnings growth expectations. |
| Competition risk (CRO/AI) | Medium | Intense competition from low-cost CROs and established diagnostic giants impacts pricing power. |
| Business quality | Medium | The business model is solid and technology-driven but remains dependent on complex long-term partnership success. |
| Dividend income | Low / none | Investors seeking immediate cash flow or yield will find no support here. |
| Execution risk | Medium / high | Success depends heavily on the integration of new technologies and the clinical success of R&D partner programs. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -46.37% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 600.61M USD | Price to earnings Ratio - | 1Y Target Price 4.2 |
Price to earnings Ratio - | 1Y Target Price 4.2 | ||
Volume (30-day avg) 107.0K shares | Beta 1.31 | 52 Weeks Range 1.33 - 3.87 | Updated Date 11/08/2026 |
52 Weeks Range 1.33 - 3.87 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| EVT Execute (Services) | Fee-for-service R&D contracts, chemical synthesis, and assay development. | Steady revenue generated from providing essential scientific work for big pharma. |
| EVT Innovate (Partnerships) | Co-investment in research, milestone payments, and future royalty streams. | Higher risk, higher reward upside from potential successful drug discoveries. |
| Geography (Global) | Operations spanning Europe, the US, and Asia to serve global pharma hubs. | Diversified geographic footprint minimizes reliance on any single regional market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 19.46 | Enterprise Value 702.36M | Price to Sales(TTM) 0.84 |
Enterprise Value 702.36M | Price to Sales(TTM) 0.84 | ||
Enterprise Value to Revenue 0.87 | Enterprise Value to EBITDA -21.37 | Shares Outstanding 355.39M | Shares Floating 294.02M |
Shares Outstanding 355.39M | Shares Floating 294.02M | ||
Percent Insiders 0.16 | Percent Institutions 0.75 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.